Group 1: Company Performance and Innovations - Several companies in the Shenzhen market are actively exploring business innovation paths related to AI technology to enhance their product offerings and strengthen their competitive advantages [2] - Xintai is applying AI in early drug discovery, clinical research, and data mining, aiming to improve innovation efficiency and reduce R&D cycles [2] - Shuanglin is expanding its product applications into the robotics sector, leveraging its self-developed planetary roller screw products to support the domestic robot joint technology [2] Group 2: International Expansion - Many Shenzhen-based private enterprises are focusing on overseas growth as a key business strategy for 2024 [3] - Wanfu Biological has over 20 years of experience in international markets, providing diagnostic reagents and instruments to over 150 countries [3] - Jianfan Biological is enhancing its overseas market presence through a revamped distributor system and international research collaborations [3] - Shuanglin is establishing localized production in Thailand, with a new factory set to begin mass production in January 2025 [3][4] Group 3: Capital Market Support - The capital market is playing a crucial role in supporting the growth of private enterprises in Shenzhen [5] - As of March, there are 2,181 private listed companies in Shenzhen, accounting for 76% of the total, with a combined market value of 22.65 trillion yuan, representing 69% of the total market value [6] - The overall performance of private enterprises in Shenzhen is stable, with reported revenues of 6.25 trillion yuan and net profits of 419.9 billion yuan for 2024 [6] - Shenzhen Stock Exchange has supported 166 private enterprises in raising 153.26 billion yuan through initial public offerings and facilitated 2,229.9 billion yuan in refinancing [6] - The exchange has also encouraged long-term investments in quality private enterprises through the introduction of several indices [7]